New treatments for melanoma involving the use of targeted agents such as vemurafenib (BrafV600E inhibitor) and ipilimumab (anti-CTLA4) are cost-prohibitive in many low- to middle-income countries. The gene discussed is CTLA4; the disease is melanoma.